COYA - Coya Therapeutics, Inc.
After hours:
| Previous Close | 4.5800 |
| Open | 4.5900 |
| Bid | 4.4100 x 1000 |
| Ask | 4.5800 x 1300 |
| Day's Range | 4.3100 - 4.5900 |
| 52 Week Range | 3.6850 - 8.0000 |
| Volume | |
| Avg. Volume | 115,426 |
| Market Cap | 45.462M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.3700 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 17.33 |
- Business Wire
Coya to Present Additional Biomarker and Brain Imaging Data for COYA 301 in Alzheimer’s Disease (AD) at the LD Micro Conference on June 7, 2023
HOUSTON, May 22, 2023--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic programs intended to enhance Treg function, including biologics and cell therapies, announced today that it will report new biomarker and brain imaging data from its open-label proof-of-concept clinical study for COYA 301 in patients with Alzheimer’s Disease at the LD Micro Conference:
ZacksHere's Why Momentum in Coya Therapeutics, Inc. (COYA) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Coya Therapeutics, Inc. (COYA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
- Business Wire
Coya Therapeutics’ COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer’s Disease
HOUSTON, May 16, 2023--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today reported results from an open-label proof-of-concept clinical study for COYA 301 in patients with AD. Results of the study will be presented on May 16, 2023, at the Keystone Conference ‘Neurodegeneration: New Biology Guiding the Next Generation of T
Simply Wall St.Is Coya Therapeutics (NASDAQ:COYA) In A Good Position To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
- Business Wire
Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial Results
HOUSTON, May 10, 2023--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the first quarter ended March 31, 2023, and provided a clinical and business update.
ACCESSWIRESidoti's Micro-Cap Virtual May Conference
Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day May Micro-cap Conference taking place Wednesday and Thursday, May 10-11, 2023. Presentation schedule is subject to change, please visit www.sidoti.com/events for the most updated version and webinar links.
- Business Wire
Coya Therapeutics, Inc. to Present at the Sidoti Virtual Investor Conference on Thursday, May 11, 2023, at 2:30pm ET
HOUSTON, May 09, 2023--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologic immunotherapies intended to enhance function of Regulatory T Cells (Tregs) function while resolving toxic inflammation, today announced management will present at the Sidoti Virtual Investor Conference Thursday May 11 at 2:30pm ET. The presentation can be accessed at:
ACCESSWIREAlzheimer’s Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments - Could Regulatory T-Cells (Tregs) Be The Answer?
In many ways, Alzheimer's disease (AD) remains a mystery. Most common in those over 65, AD is the most common form of dementia, but its exact causes remain unclear, and treatments are unable to halt or reverse disease progression.
- Business Wire
Coya Therapeutics to Present Biomarker and Preliminary Efficacy Clinical Data for COYA 301 for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Keystone Symposia Meeting for Neurodegeneration held on May 15-19th, 2023
HOUSTON, March 31, 2023--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, today announced the presentation of results from an academic clinical study in patients with Alzheimer’s Disease (AD) with Coya’s COYA 301, its proprietary investigational proprietary biologic. The presentation will be made at the 2023 Keystone Symposia Neurodegeneration: New Biology Guiding
- Business Wire
Coya Therapeutics, Inc. Provides Business Update and Reports FY 2022 Unaudited Financial Results
HOUSTON, March 29, 2023--Coya Therapeutics, Inc. (Nasdaq: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance function of Regulatory T Cells (Tregs) function, today announced its financial results for fiscal year ended December 31, 2022, and provided a clinical and business update.
News DirectThere Is No Cure For ALS, But Coya Therapeutics Might Have The Answer According To A New Clinical Study
By David Willey, Benzinga
Business WireCoya Therapeutics Strengthens Leadership Team with Addition of Arun Swaminathan, Ph.D. as Chief Business Officer
HOUSTON, March 27, 2023--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced the appointment of Arun Swaminathan, Ph.D. to the role of Chief Business Officer. In this role, Arun will be responsible for facilitating new business development partnerships, including in/out licensing opportunities, across the Company
News DirectCoya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
By David Willey, Benzinga
- Business Wire
Coya Therapeutics, Inc. to Present at the Virtual Investor Summit on Wednesday, March 29, 2023, at 11:00am ET
HOUSTON, March 23, 2023--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced management will present at the Virtual Investor Summit on Wednesday, March 29, 2023 at 11:00am ET. Investors can view the webcast here.
News DirectCoya Therapeutics’ COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study
By David Willey, Benzinga
ZacksCOYA, Dr. Reddy's Sign Deal for Proposed Abatacept Biosimilar
COYA and Dr. Reddy's enter into a license agreement where the latter will source proposed biosimilar of abatacept biosimilar to Coya to develop and commercialize COYA 302.
- Business Wire
Reminder: Coya Therapeutics to Host Conference Call Presenting Positive Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) Today at 8:00am ET
HOUSTON, March 21, 2023--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced it will host a conference call to present positive clinical data announced earlier today, of Coya’s proprietary investigational biologic combination, COYA 302, in patients with Amyotrophic Lateral Sclerosis (ALS), today at 8:00am ET.
- Business Wire
Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)
HOUSTON, March 21, 2023--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today reported 48-week clinical data for its proof-of-concept open-label study in 4 ALS patients indicating that treatment with COYA 302 appeared to ameliorate disease progression.
- Business Wire
Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases
HOUSTON, March 20, 2023--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced a worldwide agreement with Dr. Reddy’s Laboratories Limited. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as "Dr. Reddy’s"), a global pharmaceutical company. Under this agreement, Coya will in-license th
- Business Wire
Coya Therapeutics to Host Conference Call Presenting Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) on March 21, 2023, at 8:00am ET
HOUSTON, March 09, 2023--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced it will host a conference call to present clinical data of Coya’s proprietary investigational biologic combination, COYA 302, in patients with Amyotrophic Lateral Sclerosis (ALS), on Tuesday, March 21, 2023 at 8:00am ET.
News DirectThis Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine’s Next Frontier?
By David Willey, Benzinga
News DirectHouston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas
Coya Therapeutics, Inc. (NASDAQ: COYA) recently announced the presentation of results from an academic clinical study in patients with Amyotrophic Lateral Sclerosis (ALS) with Coya’s proprietary in...
- Business Wire
Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.
HOUSTON, February 27, 2023--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced the presentation of results from an academic clinical study in patients with Amyotrophic Lateral Sclerosis (ALS) with Coya’s proprietary investigational biologic combination at the 2023 MDA Clinical & Scientific Conference in Dallas,
